BioVector® MUG-CC1 人透明细胞软骨肉瘤细胞系 / MUG-CC1 Human Clear Cell Chondrosarcoma Cell Line

通用定义 / General Definition:BioVector® MUG-CC1 是一种极其稀有的、源自人类透明细胞软骨肉瘤 (Clear Cell Chondrosarcoma, CCC) 的细胞系。透明细胞软骨肉瘤是一种低度恶性的软骨肉瘤亚型，由于其独特的透明细胞形态和骨骺端的定位，在临床上极具特征性。MUG-CC1 由格拉茨医学院（Medical University of Graz）开发，是目前全球少数能够模拟这种罕见骨肿瘤生物学特性的模型之一。它为研究软骨基质代谢、细胞信号转导以及针对该罕见癌症的化疗敏感性筛选提供了至关重要的平台。

BioVector® MUG-CC1 is an extremely rare cell line derived from Human Clear Cell Chondrosarcoma (CCC). Clear cell chondrosarcoma is a low-grade malignant subtype of chondrosarcoma, clinically characterized by its unique clear cell morphology and epiphyseal localization. Developed by the Medical University of Graz, MUG-CC1 is one of the few models worldwide that recapitulates the biological properties of this rare bone tumor. It provides a crucial platform for studying cartilaginous matrix metabolism, cellular signaling, and chemotherapy sensitivity screening for this rare cancer.

BioVector® MUG-CC1 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® MUG-CC1 人透明细胞软骨肉瘤细胞

• 组织来源： 骨/软骨 (Bone/Cartilage)

• 生长特性： 贴壁生长

• 细胞形态： 上皮样、多角形，胞质清亮，具有典型的透明细胞特征

2. 培养条件

• 基础培养基： BioVector® RPMI-1640 与 DMEM (1:1) 混合培养基

• 血清添加： 10%-15% BioVector® 优质胎牛血清 (FBS)

• 培养环境： 37 摄氏度，5% CO2

• 传代比例： 1:2 至 1:3；由于细胞倍增时间较长，建议在 80%-90% 汇合度时进行传代

3. 细胞应用

• 罕见肿瘤发病机制： 研究导致软骨肉瘤透明化的分子遗传学基础。

• 生物标志物筛选： 鉴定 CCC 特异性的诊断和预后标志物。

• 分化治疗研究： 探索诱导恶性软骨细胞向成熟软骨分化的潜在途径。

4. 注意事项

• 生长缓慢： 原代来源的罕见肿瘤细胞系通常生长较慢，传代时需保持较高的接种密度。

• 基质依赖： 软骨细胞倾向于分泌大量胞外基质，培养过程中可能会观察到显著的基质沉积。

English Datasheet

1. General Product Information

• Product Name: BioVector® MUG-CC1 Human Clear Cell Chondrosarcoma Cell Line

• Tissue Source: Bone/Cartilage

• Growth Properties: Adherent

• Morphology: Epithelial-like, polygonal with clear cytoplasm, displaying typical clear cell characteristics.

2. Culture Conditions

• Basal Medium: BioVector® RPMI-1640 and DMEM (1:1) mixture

• Serum Supplement: 10%-15% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:2 to 1:3 ratio; due to a relatively long doubling time, subculture when cells reach 80%-90% confluence.

3. Applications

• Rare Tumor Pathogenesis: Investigating the molecular and genetic basis underlying the "clearing" of chondrosarcoma cells.

• Biomarker Screening: Identifying specific diagnostic and prognostic markers for CCC.

• Differentiation Therapy: Exploring potential pathways to induce the differentiation of malignant chondrocytes into mature cartilage.

4. Key Usage Notes

• Slow Proliferation: Rare tumor lines derived from patient tissue often exhibit slower growth rates; ensure a higher seeding density during subculturing to maintain viability.

• Extracellular Matrix: Chondroid cells tend to produce significant amounts of extracellular matrix (ECM), which may lead to visible matrix deposition during culture.

Note: Handle BioVector® MUG-CC1 under Biosafety Level 2 (BSL-2). Regular STR profiling is essential to confirm identity given the rarity of this line. BioVector® recommends the use of its validated specialized media and high-grade FBS to ensure long-term stability of the clear cell phenotype.

‍

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net